Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Mar;39(3):656–660. doi: 10.1128/AAC.39.3.656

Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole.

D Garcia-Hermoso 1, F Dromer 1, L Improvisi 1, F Provost 1, B Dupont 1
PMCID: PMC162600  PMID: 7793868

Abstract

Fluconazole (FCZ) has been extensively used as a primary therapy for oropharyngeal candidosis in AIDS patients. Clinical resistance to FCZ is now encountered, often related to decreased susceptibility of the isolate in vitro. We wondered if low levels in saliva play a role in the therapeutic failure, especially in patients complaining of dry mouth. Sixteen AIDS patients treated for oropharyngeal candidosis with FCZ were studied. MICs for the isolates were determined. Serum and saliva samples were collected to measure FCZ levels with a bioassay using paper disks loaded with the clinical specimens. We showed that (i) paper disks were convenient for collecting saliva in patients with dry mouth; (ii) levels in saliva depended on the FCZ dosage regimen but did not correlate with the response to therapy; (iii) correlation between concentrations in saliva and serum was poor and independent of clinical response to treatment, other therapies, or decreased salivation; and (iv) levels in saliva were always lower than MICs in patients who failed to respond to treatment. In conclusion, therapeutic failures are more likely to be related to in vitro resistance of the isolate to FCZ or insufficient dosage regimen than to decreased salivary secretion.

Full Text

The Full Text of this article is available as a PDF (210.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akova M., Akalin H. E., Uzun O., Gür D. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis. 1991 Jul;10(7):598–599. doi: 10.1007/BF01967286. [DOI] [PubMed] [Google Scholar]
  2. Bart-Delabesse E., Boiron P., Carlotti A., Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol. 1993 Nov;31(11):2933–2937. doi: 10.1128/jcm.31.11.2933-2937.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bodey G. P. Azole antifungal agents. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S161–S169. doi: 10.1093/clinids/14.supplement_1.s161. [DOI] [PubMed] [Google Scholar]
  4. Brammer K. W., Farrow P. R., Faulkner J. K. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S318–S326. doi: 10.1093/clinids/12.supplement_3.s318. [DOI] [PubMed] [Google Scholar]
  5. Cameron M. L., Schell W. A., Bruch S., Bartlett J. A., Waskin H. A., Perfect J. R. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1993 Nov;37(11):2449–2453. doi: 10.1128/aac.37.11.2449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Diamond R. D. The growing problem of mycoses in patients infected with the human immunodeficiency virus. Rev Infect Dis. 1991 May-Jun;13(3):480–486. doi: 10.1093/clinids/13.3.480. [DOI] [PubMed] [Google Scholar]
  7. Dupont B., Drouhet E. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J Med Vet Mycol. 1988 Feb;26(1):67–71. doi: 10.1080/02681218880000081. [DOI] [PubMed] [Google Scholar]
  8. Ebden P., Neill P., Farrow P. R. Sputum levels of fluconazole in humans. Antimicrob Agents Chemother. 1989 Jun;33(6):963–964. doi: 10.1128/aac.33.6.963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fan-Havard P., Capano D., Smith S. M., Mangia A., Eng R. H. Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother. 1991 Nov;35(11):2302–2305. doi: 10.1128/aac.35.11.2302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fox R., Neal K. R., Leen C. L., Ellis M. E., Mandal B. K. Fluconazole resistant candida in AIDS. J Infect. 1991 Mar;22(2):201–204. doi: 10.1016/0163-4453(91)91767-r. [DOI] [PubMed] [Google Scholar]
  11. Grant S. M., Clissold S. P. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs. 1990 Jun;39(6):877–916. doi: 10.2165/00003495-199039060-00006. [DOI] [PubMed] [Google Scholar]
  12. Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Just-Nübling G., Gentschew G., Meissner K., Odewald J., Staszewski S., Helm E. B., Stille W. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis. 1991 Nov;10(11):917–921. doi: 10.1007/BF02005444. [DOI] [PubMed] [Google Scholar]
  14. McCarthy G. M., Mackie I. D., Koval J., Sandhu H. S., Daley T. D. Factors associated with increased frequency of HIV-related oral candidiasis. J Oral Pathol Med. 1991 Aug;20(7):332–336. doi: 10.1111/j.1600-0714.1991.tb00940.x. [DOI] [PubMed] [Google Scholar]
  15. Ng T. T., Denning D. W. Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach. J Infect. 1993 Mar;26(2):117–125. doi: 10.1016/0163-4453(93)92707-4. [DOI] [PubMed] [Google Scholar]
  16. Odds F. C. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother. 1993 Apr;31(4):463–471. doi: 10.1093/jac/31.4.463. [DOI] [PubMed] [Google Scholar]
  17. Oliary J., Tod M., Louchahi K., Petitjean O., Frachet B., Le Gros V., Brion N. Influence of local radiotherapy on penetration of fluconazole into human saliva. Antimicrob Agents Chemother. 1993 Dec;37(12):2674–2677. doi: 10.1128/aac.37.12.2674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pfaller M. A., Dupont B., Kobayashi G. S., Müller J., Rinaldi M. G., Espinel-Ingroff A., Shadomy S., Troke P. F., Walsh T. J., Warnock D. W. Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother. 1992 Sep;36(9):1805–1809. doi: 10.1128/aac.36.9.1805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Powderly W. G. Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS. 1992 Jun;6(6):604–605. [PubMed] [Google Scholar]
  20. Powderly W. G., Robinson K., Keath E. J. Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus-positive patients: evidence for two patterns of recurrence. J Infect Dis. 1993 Aug;168(2):463–466. doi: 10.1093/infdis/168.2.463. [DOI] [PubMed] [Google Scholar]
  21. Rex J. H., Hanson L. H., Amantea M. A., Stevens D. A., Bennett J. E. Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography. Antimicrob Agents Chemother. 1991 May;35(5):846–850. doi: 10.1128/aac.35.5.846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Smith D., Boag F., Midgley J., Gazzard B. Fluconazole resistant candida in AIDS. J Infect. 1991 Nov;23(3):345–346. doi: 10.1016/0163-4453(91)93584-y. [DOI] [PubMed] [Google Scholar]
  23. Tucker R. M., Denning D. W., Hanson L. H., Rinaldi M. G., Graybill J. R., Sharkey P. K., Pappagianis D., Stevens D. A. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992 Jan;14(1):165–174. doi: 10.1093/clinids/14.1.165. [DOI] [PubMed] [Google Scholar]
  24. Tucker R. M., Williams P. L., Arathoon E. G., Levine B. E., Hartstein A. I., Hanson L. H., Stevens D. A. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother. 1988 Mar;32(3):369–373. doi: 10.1128/aac.32.3.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Warnock D. W. Azole drug resistance in Candida species. J Med Microbiol. 1992 Oct;37(4):225–226. doi: 10.1099/00222615-37-4-225. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES